1. Home
  2. INDP vs BLND Comparison

INDP vs BLND Comparison

Compare INDP & BLND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Indaptus Therapeutics Inc.

INDP

Indaptus Therapeutics Inc.

HOLD

Current Price

$2.63

Market Cap

350.4M

Sector

Health Care

ML Signal

HOLD

Logo Blend Labs Inc.

BLND

Blend Labs Inc.

HOLD

Current Price

$1.72

Market Cap

411.6M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
INDP
BLND
Founded
2000
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
350.4M
411.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
INDP
BLND
Price
$2.63
$1.72
Analyst Decision
Buy
Analyst Count
0
6
Target Price
N/A
$4.13
AVG Volume (30 Days)
73.1K
2.2M
Earning Date
05-11-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
58.33
EPS
N/A
N/A
Revenue
N/A
$123,585,000.00
Revenue This Year
N/A
$12.62
Revenue Next Year
N/A
$14.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.92
$1.18
52 Week High
$10.57
$4.49

Technical Indicators

Market Signals
Indicator
INDP
BLND
Relative Strength Index (RSI) 48.83 49.33
Support Level $2.42 $1.58
Resistance Level $3.08 $1.87
Average True Range (ATR) 0.22 0.11
MACD -0.01 -0.01
Stochastic Oscillator 54.55 32.69

Price Performance

Historical Comparison
INDP
BLND

About INDP Indaptus Therapeutics Inc.

Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.

About BLND Blend Labs Inc.

Blend Labs Inc is a cloud-based platform software platform that powers the digital interface between financial services firms and consumers. It supports and simplifies applications for mortgages, consumer loans, and deposit accounts. Its operating segment is Blend Platform segment which comprises a suite of products that power the entire origination process from back-end workflows to consumer experience. The key revenue for the company is generated from the Blend Platform segment. Company has it's assets in united states, India and Mexico regions.

Share on Social Networks: